# Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China

> **NCT03020134** · PHASE1 · COMPLETED · sponsor: **Ascletis Pharmaceuticals Co., Ltd.** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Ravidasvir
- **DRUG:** Danoprevir
- **DRUG:** Ritonavir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03020134
- **Lead sponsor:** Ascletis Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-15
- **Primary completion:** 2016-08-22
- **Final completion:** 2016-08-22
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2018-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03020134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03020134, "Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03020134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*